Connect Biopharma Holdings Limited (CNTB)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
2.26 USD
-0.25
(-9.960%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.25 -0.01 (-0.010%) ⇩ (July 13, 2026, 7:41 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 7:07 a.m. EDT
Connect Biopharma presents a classic biotech dilemma: a 'strong buy' analyst consensus driven by potential clinical milestones clashes violently with the reality of a company burning cash and trading at a negative earnings multiple. Fundamentally, the business is under severe stress; operating cash flow is negative $57 million, free cash flow is negative $34 million, and the company is hemorrhaging value with no dividend to cushion the blow. While the stock has recovered significantly from its 2022 lows, the trajectory remains precarious with a massive gap between the current price and the analyst mean target, implying a reliance on binary events rather than sustainable operations. The options market reflects this uncertainty with low participation and mixed signals, offering no clear roadmap for the near term. Until the company demonstrates a path to profitability or a definitive catalyst that bridges the valuation gap, the investment case remains speculative. |
| Model | MAE |
|---|---|
| MSTL_126 ✓ | 0.217027 |
| AutoTheta | 0.251688 |
| AutoETS | 0.259725 |
| AutoARIMA | 0.260236 |
| MSTL | 0.268532 |
Forecast horizon: 60 days | Selected: MSTL_126
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 1.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.245 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.626 |
| Revenue per Share | 0.004 |
| Market Cap | 142,298,304 |
| Forward P/E | -2.77 |
| Website | https://www.connectbiopharm.com |
As of July 11, 2026, 7:07 a.m. EDT: Options activity is sparse and lacks directional conviction. Call volume is negligible across expirations, while put activity is minimal but shows fresh inflow at the money strikes recently. Open interest is heavily skewed toward out-of-the-money calls at the $5.00 strike, suggesting speculative hopes for a massive rally, yet the lack of corresponding call volume and the presence of new put buying indicate a market waiting for a catalyst rather than actively betting on a specific direction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.78014183 |
| Address1 | 3,580 Carmel Mountain Road |
| Address2 | Suite 200 |
| All Time High | 29.274 |
| All Time Low | 0.51 |
| Ask | 2.9 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 886,140 |
| Average Daily Volume3 Month | 352,481 |
| Average Volume | 352,481 |
| Average Volume10Days | 886,140 |
| Bid | 1.78 |
| Bid Size | 2 |
| Book Value | 0.68 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.26 |
| Current Ratio | 3.228 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.49 |
| Day Low | 2.23 |
| Debt To Equity | 1.626 |
| Display Name | Connect Biopharma |
| Earnings Timestamp End | 1,758,283,200 |
| Earnings Timestamp Start | 1,757,069,940 |
| Ebitda | -65,539,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.479 |
| Enterprise To Revenue | 416.126 |
| Enterprise Value | 96,957,304 |
| Eps Current Year | -1.05833 |
| Eps Forward | -0.81667 |
| Eps Trailing Twelve Months | -1.15 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.303 |
| Fifty Day Average Change | -0.042999983 |
| Fifty Day Average Change Percent | -0.018671291 |
| Fifty Two Week Change Percent | 78.01418 |
| Fifty Two Week High | 3.82 |
| Fifty Two Week High Change | -1.56 |
| Fifty Two Week High Change Percent | -0.40837696 |
| Fifty Two Week Low | 1.23 |
| Fifty Two Week Low Change | 1.03 |
| Fifty Two Week Low Change Percent | 0.83739835 |
| Fifty Two Week Range | 1.23 - 3.82 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,616,160,600,000 |
| Float Shares | 18,850,118 |
| Forward Eps | -0.81667 |
| Forward P E | -2.7673357 |
| Free Cashflow | -33,877,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 64 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 233,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31824 |
| Held Percent Institutions | 0.55556 |
| Implied Shares Outstanding | 62,963,853 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-03-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California. |
| Long Name | Connect Biopharma Holdings Limited |
| Market | us_market |
| Market Cap | 142,298,304 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_706016439 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -64,606,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 158,039,271 |
| Number Of Analyst Opinions | 8 |
| Open | 2.49 |
| Operating Cashflow | -57,252,000 |
| Operating Margins | -116.01775 |
| Payout Ratio | 0.0 |
| Phone | 877 245 2787 |
| Post Market Change | -0.009500027 |
| Post Market Change Percent | -0.42035517 |
| Post Market Price | 2.2505 |
| Post Market Time | 1,783,986,072 |
| Previous Close | 2.51 |
| Price Eps Current Year | -2.1354396 |
| Price Hint | 4 |
| Price To Book | 3.3235295 |
| Price To Sales Trailing12 Months | 610.72235 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.859 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -0.25 |
| Regular Market Change Percent | -9.96016 |
| Regular Market Day High | 2.49 |
| Regular Market Day Low | 2.23 |
| Regular Market Day Range | 2.23 - 2.49 |
| Regular Market Open | 2.49 |
| Regular Market Previous Close | 2.51 |
| Regular Market Price | 2.26 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 481,495 |
| Return On Assets | -0.54201 |
| Return On Equity | -1.0294 |
| Revenue Per Share | 0.004 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,963,853 |
| Shares Percent Shares Out | 0.0211 |
| Shares Short | 1,327,642 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,166,987 |
| Short Name | Connect Biopharma Holdings Limi |
| Short Percent Of Float | 0.0299 |
| Short Ratio | 2.98 |
| Source Interval | 15 |
| State | CA |
| Symbol | CNTB |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.125 |
| Target Median Price | 7.0 |
| Total Cash | 46,034,000 |
| Total Cash Per Share | 0.731 |
| Total Debt | 693,000 |
| Total Revenue | 233,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.360555 |
| Two Hundred Day Average Change | -0.10055494 |
| Two Hundred Day Average Change Percent | -0.04259801 |
| Type Disp | Equity |
| Volume | 481,495 |
| Website | https://www.connectbiopharm.com |
| Zip | 92,130 |